CN102858375A - 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用 - Google Patents

载有干扰核糖核酸的细胞微粒子、其制备方法及其应用 Download PDF

Info

Publication number
CN102858375A
CN102858375A CN2010800662810A CN201080066281A CN102858375A CN 102858375 A CN102858375 A CN 102858375A CN 2010800662810 A CN2010800662810 A CN 2010800662810A CN 201080066281 A CN201080066281 A CN 201080066281A CN 102858375 A CN102858375 A CN 102858375A
Authority
CN
China
Prior art keywords
small interfering
interfering rnas
microvesicles
preparation methods
containing small
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2010800662810A
Other languages
English (en)
Other versions
CN102858375B (zh
Inventor
张辰宇
曾科
刘丹青
张玉婧
顾宏伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Micromedmark Biotech Co Ltd
Original Assignee
Jiangsu Micromedmark Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Micromedmark Biotech Co Ltd filed Critical Jiangsu Micromedmark Biotech Co Ltd
Publication of CN102858375A publication Critical patent/CN102858375A/zh
Application granted granted Critical
Publication of CN102858375B publication Critical patent/CN102858375B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)

Abstract

含有干扰核糖核酸的细胞微粒子、其制备方法及其应用。还提供包括含有干扰核糖核酸的药物组合和试剂盒。含有干扰核糖核酸的细胞微粒子以及包括该细胞微粒子的药物组合和试剂盒可用于研究干扰核糖核酸对受体细胞的影响作用。由于含有干扰核糖核酸的细胞微粒子能够稳定、高效、特异性地输送干扰核糖核酸，因而可用于治疗相关疾病。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201080066281.0A 2010-05-26 2010-05-26 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用 Active CN102858375B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/073262 WO2011147086A1 (zh) 2010-05-26 2010-05-26 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用

Publications (2)

Publication Number Publication Date
CN102858375A true CN102858375A (zh) 2013-01-02
CN102858375B CN102858375B (zh) 2016-08-10

Family

ID=45003208

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080066281.0A Active CN102858375B (zh) 2010-05-26 2010-05-26 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用

Country Status (3)

Country Link
US (1) US9376679B2 (zh)
CN (1) CN102858375B (zh)
WO (1) WO2011147086A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856477B2 (en) * 2012-11-13 2018-01-02 Codiak Biosciences, Inc. Delivery of therapeutic agent
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015186013A1 (en) 2014-06-04 2015-12-10 Capsugel Belgium Nv Stable dosage form articles for oral administration
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
MX2017015962A (es) 2015-06-10 2018-07-06 Univ Texas Uso de exosomas para el tratamiento de enfermedades.
LT3394093T (lt) 2015-12-23 2022-04-25 Modernatx, Inc. Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
MA43587A (fr) 2016-01-10 2018-11-14 Modernatx Inc Arnm thérapeutiques codant pour des anticorps anti-ctla-4
US20190216857A1 (en) * 2016-09-09 2019-07-18 Cornell University Delivery of nucleic acids, proteins and small molecules in vitreous vesicular bodies
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
WO2023156532A1 (en) * 2022-02-18 2023-08-24 Servicio Andaluz De Salud ISOLATED PLASMA MEMBRANE-DERIVED VESICLES (PMdV) FOR USE IN THE TREATMENT OF VIRAL INFECTIONS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070917A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
CN101386848A (zh) * 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
CN101432432A (zh) * 2006-05-03 2009-05-13 扬·奥洛夫·洛特温尔 核酸向细胞的胞外体转移
WO2009100029A1 (en) * 2008-02-01 2009-08-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
WO2009147519A1 (en) * 2008-06-06 2009-12-10 Centre National De La Recherche Scientifique - Cnrs- Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241176A1 (en) 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US20030124513A1 (en) 2001-05-29 2003-07-03 Mcswiggen James Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
WO2005032561A1 (ja) 2003-10-03 2005-04-14 Riken ＨＩＶ−Ｖｐｒの機能に関する発明
CA2609260A1 (en) 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
CN1948475B (zh) 2004-10-13 2010-12-08 厦门大学 可用于治疗艾滋病的重组表达载体、经改造的造血干细胞和方法
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CA2756670A1 (en) 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
CN101869715A (zh) 2010-05-26 2010-10-27 江苏命码生物科技有限公司 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070917A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
CN101432432A (zh) * 2006-05-03 2009-05-13 扬·奥洛夫·洛特温尔 核酸向细胞的胞外体转移
WO2009100029A1 (en) * 2008-02-01 2009-08-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
WO2009147519A1 (en) * 2008-06-06 2009-12-10 Centre National De La Recherche Scientifique - Cnrs- Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna
CN101386848A (zh) * 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHARON A等: "Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells", <THROMB HAEMOST> *
NOBUYOSHI KOSAKA等: "Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells", <THE JOURNAL OF BIOLOGICAL CHEMISTRY> *
朱磊 等: "Exosomes 在肿瘤免疫方面的研究进展", 《中国生物制品学杂志》 *

Also Published As

Publication number Publication date
US20130209544A1 (en) 2013-08-15
US20140302119A2 (en) 2014-10-09
WO2011147086A1 (zh) 2011-12-01
US9376679B2 (en) 2016-06-28
CN102858375B (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
CN102858375A (zh) 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用
WO2011159684A3 (en) Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
WO2012110636A3 (en) Carrier peptides for cell delivery
WO2011094572A3 (en) Hanging drop devices, systems and/or methods
MX2013005654A (es) Composiciones y metodos para la produccion de acido 3-hidroxipropionico.
NZ602139A (en) Plant peptide gamma-zein for delivery of biomolecules into plant cells
EP4269584A3 (en) Selective antisense compounds and uses thereof
WO2010099383A3 (en) Compositions and methods for ex vivo hepatic nucleic acid delivery
MX346926B (es) Proceso para transfeccion de plantas.
CA2817172C (en) Stem cell suspension
IN2014CN02447A (zh)
WO2011018423A3 (de) Vorrichtung und verfahren zur behandlung von lebenden zellen mittels eines plasmas
NZ598419A (en) Use of dendrimer nanotechnology for delivery of biomolecules into plant cells
WO2013059582A3 (en) Small molecule inhibitors of histone deacteylases
WO2012103261A3 (en) Compositions and methods for succinate production
WO2013071113A3 (en) Method of fracturing using mannanohydrolase enzyme breaker
WO2012098537A8 (en) Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2010039802A3 (en) Methods and compositions for isolating nucleic acid
WO2011103435A3 (en) Methods for forming protected organoboronic acids
WO2012094193A3 (en) Methods for enhancing the delivery of gene-transduced cells
WO2008150276A3 (en) Virus coated nanoparticles and uses thereof
WO2014012115A3 (en) Method for inducing cells to less mature state
EP3138850B8 (en) Compositions containing deoxycholic acid and 10% deionized water in ethanol, directed to the purification of deoxycholic acid
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant